Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
MetadataShow full item record
We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS) (n = 50, 32.0%), angioimmunoblastic T-cell lymphoma (AITL) (n = 44, 28.2%), anaplastic large-cell lymphoma (ALCL) ALK negative (n = 23, 14.7%), ALCL ALK positive (n = 16, 10.3%), and other (n = 23, 14.7%). Most patients received CHOP (66.0%) and 13.0% received an autologous hematopoietic progenitor cell transplant (HPCT). With a median follow-up of 63.4 months, 5-year overall survival (OS) and progression-free survival (PFS) was 38.8% and 19.8% respectively. Independent risk factors for inferior OS were age >60 years, International Prognostic Index (IPI) ≥ 2 and lack of complete response to induction. When responding patients were compared by receipt of an autologous HPCT versus not, HPCT was associated with improved PFS (p = .001) and OS (p = .046) and remained significant for PFS in multivariate analysis suggesting a possible therapeutic benefit.
The Institute of Cancer Research (Grant ID: Unspecified)
Version of record
Peripheral T-cell lymphoma
hematopoietic progenitor cell transplant
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Combined Modality Therapy
Hematopoietic Stem Cell Transplantation
Lymphoma, T-Cell, Peripheral
Medicine (RMH Smith Cunningham)
License start date
Leuk Lymphoma, 2018, 59 (7), pp. 1586 - 1595
Showing items related by title, author, creator and subject.
Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). Chisholm, JC; Merks, JHM; Casanova, M; Bisogno, G; Orbach, D; Gentet, J-C; Thomassin-Defachelles, A-S; Chastagner, P; Lowis, S; Ronghe, M; McHugh, K; van Rijn, RR; Hilton, M; Bachir, J; Fürst-Recktenwald, S; Geoerger, B; Oberlin, O; European paediatric Soft tissue sarcoma Study Group (EpSSG) and the European Innovative Therapies for Children with Cancer (ITCC) Consortium (2017-09)PURPOSE: We evaluated the role of bevacizumab as part of the multi-modality treatment of children and adolescents with metastatic rhabdomyosarcoma (RMS) or non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). PATIENTS AND ...
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. Scagliotti, GV; Gaafar, R; Nowak, AK; Reck, M; Tsao, AS; van Meerbeeck, J; Vogelzang, NJ; Nakano, T; von Wangenheim, U; Velema, D; Morsli, N; Popat, S (2017-09)Malignant pleural mesothelioma (MPM) is a rare but aggressive disease: median survival is 6 to 9 months if untreated. Standard first-line treatment for patients with unresectable MPM is cisplatin/pemetrexed, with a median ...
MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial. Patel, UB; Brown, G; Machado, I; Santos-Cores, J; Pericay, C; Ballesteros, E; Salud, A; Isabel-Gil, M; Montagut, C; Maurel, J; Ramón-Ayuso, J; Martin, N; Estevan, R; Fernandez-Martos, C (2017-02-01)Background: Primary chemotherapy has been tested as a possible approach for patients with high risk features but predicted clear mesorectal margins on preoperative MRI assessment. This study investigates the prognostic ...